Dolutegravir

1. Dolutegravir induces fibrosis.

   Reviewpreclinical models

   Weight gain, adipose tissue remodeling and cardiometabolic disease in people with HIV · Current opinion in HIV and AIDS · 1 Oct 2026

1. Dolutegravir raises the risk of hypertension in humans (doubles the risk).

   Reviewin people with HIV

   Weight gain in people with HIV in Africa and Asia: a review of causes, consequences, and management implications · Current opinion in HIV and AIDS · 1 Oct 2026

Hypertension →

1. Dolutegravir lowers the risk of type 2 diabetes in humans (aIRR=0.4).

   “After adjusting for age, BMI, and duration on antiretroviral therapy, Dolutegravir Initiators (aIRR=0.4) and Dolutegravir Transitioners (aIRR=0.4) had a lower risk than Non-Dolutegravir Users.”

   Humansafter adjusting for age, BMI, and duration on antiretroviral therapy, vs non-dolutegravir users

   Exploring the Relationship Between Dolutegravir and Diabetes Using Routine Data of Patients on Anti-Retroviral Treatment in a High HIV Prevalence Setting · Medical research archives · 1 Feb 2026

Type 2 diabetes →